These may contribute to the progressionof NAFLD by dramatically altering metabolic processes.50−52 DHEAS and CYP2C19 were also identified as importantfactors characterizing CLD in the mixOmics analysis and may be involvedin the pathology independent of the subtype. Here, CYP2C19 is linked to metabolic dysfunction-associated steatotic liver disease.